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Abstract:  Deficits in neuroplasticity are hypothesized to underlie the pathophysiology of major depressive disorder 
(MDD): the effectiveness of antidepressants is thought to be related to the normalization of disrupted synaptic trans- 
mission and neurogenesis. The cyclic adenosine monophosphate (cAMP) signaling cascade has received considerable  
attention for its role in neuroplasticity and MDD. However components of a closely related pathway, the cyclic guanosine 
monophosphate (cGMP) have been studied with much lower intensity, even though this signaling transduction cascade is 
also expressed in the brain and the activity of this pathway has been implicated in learning and memory processes. Cyclic 
GMP acts as a second messenger; it amplifies signals received at postsynaptic receptors and activates downstream effector 
molecules resulting in gene expression changes and neuronal responses. Phosphodiesterase (PDE) enzymes degrade 
cGMP into 5’GMP and therefore they are involved in the regulation of intracellular levels of cGMP. Here we review a 
growing body of evidence suggesting that the cGMP signaling cascade warrants further investigation for its involvement 
in MDD and antidepressant action.  
Keywords: Major Depression, cyclic guanosine monophosphate, neurogenesis, neuroplasticity, phophodiesterases, cyclases, 
antidepressants, pharmacology. 
1. INTRODUCTION 
  Major depressive disorder (MDD) is a chronic and highly 
disabling condition. It is the most common mood disorder: 
up to 17% of the population suffers from this condition at 
some point during their lifetimes. While antidepressants have 
been shown to be effective in treating the symptoms of MDD 
in 60-70% of patients, 30-40% of patients do not respond to 
pharmacotherapy [1, 2]. Furthermore, antidepressants must 
be taken chronically for several weeks before treatment re-
sponse is achieved and it is still unclear what are the mecha-
nisms by which these drugs relieve the clinical symptoms of 
MDD. Evidence from clinical and preclinical research accu-
mulated in recent years support the concept that aberrant 
neuroplasticity, including functional synaptic plasticity and 
structural plasticity, in the hippocampus and prefrontal cortex, 
might underlie MDD [3, 4]. Intracellular cyclic adenosine 
monophosphate (cAMP) signaling activated by brain-derived 
neurotrophic factor (BDNF) has been shown to be a pivotal 
player in neuroplasticity and MDD; moreover, studies   
have demonstrated that treatment with antidepressants   
can alter the expression of components of this signaling 
pathway in rodents [5-7]. Unfortunately, earlier findings 
have been inconsistently replicated making it premature to 
conceptualize translational strategies for new antidepressant 
pharmacotherapy targeting the cAMP signaling. The cyclic 
guanosine monophosphate (cGMP) signaling pathway is   
an intracellular nucleotide cascade that is also involved in  
neuroplasticity. It is closely related to cAMP signaling, but it  
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has received little attention in the biology of MDD and   
antidepressant action. The cGMP signaling cascade consists  
of a number of different elements that can regulate cGMP  
levels and influence downstream cellular responses. Fig. (1)  
depicts the presynaptic and postsynaptic elements of the   
cGMP signaling pathway in the central nervous system;   
these elements are expressed in the hippocampus, a brain   
region that has been implicated in MDD [8, 9]. Pharma- 
cotherapy targeting different elements of the cGMP pathway  
is currently available; this class of drugs includes phosphodi- 
esterase inhibitors, which increase cGMP signaling. In this  
review, we summarize the evidence that supports the role of  
cGMP signaling in neuroplasticity and in the pathophysiology  
of MDD and antidepressant treatment response, with a   
specific focus on the role of phosphodiesterases (PDEs). 
2. cGMP SIGNALING COMPONENTS AND THEIR 
DISTRIBUTION IN THE BRAIN 
2.1. cGMP Synthesis: pGC and sGC 
  The synthetic enzyme guanylate/guanylyl cyclase (GC) 
converts guanosine triphosphate (GTP) to 3’-5’-cyclic 
guanosine monophosphate to produce the second messenger 
molecule known as cGMP. The production of cGMP by GC 
can occur in two different ways: 1) following activation of 
membrane bound guanylate cyclase (particulate GC or pGC) 
[10, 11] and 2) following activation of soluble guanylate 
cyclase (sGC, also called NO receptors) in the cytoplasm by 
the diffusible second messenger molecule, nitric oxide (NO) 
[12, 13]. 
  Particulate GC is composed of two subfamilies: the pep-
tide hormone receptor subfamily, which binds natriuretic 
peptides, and the Ca
2+-modulated ROS-GC (rod outer 716    Current Neuropharmacology, 2011, Vol. 9, No. 4  Reierson et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The cGMP signaling pathway. Presynaptic (top) and postsynaptic (bottom) elements of the cGMP signaling cascade are represented. 
AMPAR = 2-amino-3-(5-methyl-3-oxo-1,2-oxal-4-yl)propanoic acid receptor; CaMK = calcium-calmodium-dependent kinase; cAMP = cyclic 
adenosine monophosphate; cGMP = cyclic guanosine monophosphate; CNG = cyclic nucleotide gated channels; NO = nitric oxide;   
nNO = neuronal NO; PDE = phosphodiesterase; PI3K/AKT/Gsk3 = phosphoinositide 3-kinase/protein kinase B (aka AKT)/glycogen   
synthase kinase 3; PKGI = cGMP dependent protein kinase I; PKGII = cGMP dependent protein kinase II; sGC = soluble guanylate cyclase; 
VASP = vasodilator-stimulated phosphoprotein. 
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segment-derived guanylate cyclase) subfamily, which is 
linked with the senses of vision, olfaction and taste, and 
light-regulated pinealocytes [1, 14-16]. The isoforms of pGC  
expressed in the brain include guanylate cyclase A/natriuretic 
peptide receptor 1 (GC-A/Npr1), guanylate cyclase B/natriuretic 
peptide receptor 2 (GC-B/Npr2), guanylate cyclase 2D (GC-
D/GUCY2D); while two eye-specific GC have been identi-
fied in mammals (designed GC-E and GC-F or RetGC-1 and 
RetGC-2 in humans) [17-19]. GC-A/Npr1 is activated by 
atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP) and the mRNA is expressed in the subfornical organ, 
medial habenula, cerebellum and olfactory bulb [20, 21]. 
GC-B/Npr2 is activated by natriuretic peptide type C (CNP) 
and the mRNA is expressed in the pineal gland, cerebellum, 
cortex, hippocampus, hypothalamus, olfactory bulb, neural 
lobe of the pituitary gland, and thalamus [21, 22]. GC-D   
is expressed in the olfactory bulb in rodents, but it is a   
pseudogene in humans [23]. 
  Soluble GC exists as a heterodimer composed of differ-
ent combinations of  subunits (1 or 2) and  subunits 
(1 or 2); all sGC subunits mRNAs are expressed in the 
brain with the exception of the 2 subunit mRNAs [24]. 
Both 1 and 2 sGC subunits mRNAs are expressed in the 
cerebral cortex and olfactory bulb; 1 is also expressed in 
striatum and pallidum and 2 is also expressed in hippocam-
pus and medulla [21]. The 1 sGC subunit mRNA is   
expressed throughout the brain, with predominant expression 
in the cerebral cortex, hippocampus, lateral septal complex, 
olfactory bulb, and striatum [21, 24]. In the hippocampus, 
the sGC heterodimer is composed of 2 and 1 subunits 
[25].  
2.2. cGMP Degradation: PDEs 
  Several different enzymes of the phosphodiesterase 
(PDE) family are capable of cleaving cGMP into 5’-GMP. 
PDEs are classified as cAMP specific (PDE4, PDE7, and 
PDE8), cGMP specific (PDE5, PDE6, and PDE9), or dual 
substrate (PDE1, PDE2, PDE3, PDE10, and PDE11) [26, 
27]. Dual substrate PDEs are able to hydrolyze both cAMP 
and cGMP. The specificity of a dual substrate PDE for each 
cyclic nucleotide substrate is determined by the orientation 
of an invariant glutamine in the binding pocket of the cata-
lytic domain of the PDE, a concept that is termed “glutamine 
switch” [28-30]. The orientation of the glutamine is thought 
to be determined by the presence of neighboring residues 
that constrain the rotation of the glutamine to only allow the 
purine ring of one or the other cyclic nucleotides to bind via 
H bond formation; free rotation of the glutamine allows both 
substrates to bind [30, 31]. The binding affinities (Km val-
ues), the catalytic hydrolyzing activities (Vmax, Kcat) and the 
presence of specific domains in the N-terminal region of 
these genes reveal much information about how these PDEs 
might be uniquely suited to regulate cyclic nucleotide cross-
talk. The presence of N-terminal domains is especially   
influential, as activity in these domains can cause conforma-
tional changes in the catalytic domain of the PDE, changing 
the Km and Vmax of the enzyme toward cyclic nucleotide   
substrates [30, 32]. 
  In the following two paragraphs, we will summarize the 
CNS expression of cGMP specific PDEs (PDE5, PDE6, 
PDE9) and dual substrate PDEs (PDE1, PDE2, PDE3, 
PDE10, and PDE11).  
  All cGMP specific PDEs are expressed in the brain. In 
the rodent brain, PDE5A mRNA expression has been re-
ported in the purkinje cells of the cerebellum; strong staining 
has also been observed in scattered cells in the hippocampus, 
including pyramidal cells of CA1, CA2 and CA3, as well as 
in the dentate gyrus [33]. PDE6 was initially thought to be 
limited to the retina; however, PDE6B mRNA expression 
has also been reported in mouse hippocampus [34]. CNS 
expression of the PDE9A mRNA in the rodent brain has 
been reported in the purkinje cells and granule cells of the 
cerebellum, olfactory bulb and tubercle, caudate putamen, 
and CA1 and dentate gyrus areas of the hippocampus [35-
37]. In the human brain, PDE9 mRNA expression has been 
reported in the insular and visual cortices as well as in the 
CA1, CA2 and CA3 subfields, and dentate gyrus of the hip-
pocampal formation [38].  
  All dual substrate cGMP are also expressed in the brain. 
In rodents, in situ hybridization and immunohistochemistry 
studies demonstrated that the PDE1A isoform is expressed in 
the following brain areas: cerebral cortex, pyramidal cells of 
the hippocampus, and striatum [39, 40]. PDE1B is also ex-
pressed in several brain areas including the caudate-putamen, 
nucleus accumbens, dentate gyrus of hippocampus, olfactory 
tubercle, medial thalamic nuclei, and brainstem [39, 40]. 
PDE1C mRNA is expressed in the granule cells of the cere-
bellum, caudate-putamen, olfactory tubercle, and brainstem 
of the rodent brain [41]. In the human brain, hippocampal 
PDE1B expression has been reported in the granule cells of 
the dentate gyrus and in pyramidal cells [42]. PDE2 mRNA 
is expressed in the rodent medial habenula, olfactory bulb 
and tubercle, cortex, amygdala, striatum, and hippocampus 
[33]. Within the rodent hippocampus, PDE2 protein is   
expressed in the pyramidal cells of CA1 to CA3 subfields and 
in the granule cells of the dentate gyrus [37]. In the human 
brain, PDE2 mRNA expression has been found in the insular 
and visual cortices as well as in the hippocampal formation 
[38]. In a systematic immunohistochemistry study, PDE2A 
protein was expressed in the limbic system, including hippo-
campus, basal ganglia, amygdala, isocortex, habenula, and 
interpeduncular nucleus [43]. The mRNAs of both PDE3A 
and PDE3B isoforms are expressed in the rodent hippocam-
pus, with PDE3A also displaying expression in the striatum 
and PDE3B displaying expression in the cerebellum [44]. 
According to immunohistochemistry studies, PDE10A is 
expressed in the pyramidal cells and dentate gyrus of the 
hippocampus, cortex, granule cells of the cerebellum, and is 
especially enriched in the striatum [45-47]. The mRNA and 
protein of PDE11A are expressed in the trigeminal ganglion, 
neocortex, spinal trigeminal nucleus, and purkinje cells of 
the cerebellum of rats [48]. In the human brain, PDE11A4 
protein is expressed in the pituitary [49]. 
2.3. cGMP Downstream Effectors: PKG/cGK 
  The downstream effectors of cGMP include protein 
kinases, cyclic nucleotide gated channels (CNG), and cAMP 
specific PDEs. The major downstream effector of cGMP   
is the protein kinase G (PKG), which is alternatively referred 
to as cyclic GMP dependent protein kinase (cGK). PKGs 718    Current Neuropharmacology, 2011, Vol. 9, No. 4  Reierson et al. 
belong to a family of serine/threonine kinases because they 
phosphorylate target protein substrates at specific structural 
motifs. There are two different PKG genes, PRKG1  and 
PRKG2 that encode cytosolic PKGI/cGKI and membrane-
bound PKGII/cGKII, respectively. PKGI can be alternatively 
spliced at the N-terminal into two isoforms, PKGI  
and PKGI, varying in tissue distribution, subcellular 
localization, and substrate interaction [50]. 
  PKG is comprised of three different functional domains: 
N-terminal domain containing regulatory sites, a regulatory 
domain containing cGMP binding sites, and a catalytic do-
main in the C-terminal region. The regulatory sites of the N-
terminal domain of PKG include domains that influence di-
merization, autoinhibitory, autophosphorylation, affinity and 
cooperative behavior, and intracellular localization. Upon 
binding of two molecules of cGMP to the two binding sites 
present in the regulatory domain of PKG, the autoinhibitory 
site that normally inhibits the catalytic domain of PKG is 
removed, thus activating the protein. The catalytic domain of 
PKG is located at the C-terminal end and contains binding 
sites for Mg
2+, ATP, and the target protein. Once activated, 
PKG phosphorylates target proteins at RKRKXST structural 
motifs [51]. 
  Although PKGI was previously reported to display lim-
ited expression restricted to the Purkinje cells of the cerebel-
lum, neurons in the nigrostriatal pathway, and dorsomedial 
nucleus of the hypothalamus, further studies now demon-
strate that PKGI is expressed in additional brain areas such 
as the hippocampus, olfactory bulb and amygdala [21, 52, 
53]. PKGI expression has been found in the following mouse 
brain structures: cerebellum, hippocampus, dorsomedial hy-
pothalamus, medulla, subcommisural organ, cerebral cortex, 
amygdala, habenula, hypothalamus, olfactory bulb, pituitary, 
and retina, with isoform specific PKGI expression in the 
cerebellum and medulla and PKGI expression in the cortex, 
hippocampus, hypothalamus, and olfactory bulb [9]. PKGII 
is widely expressed throughout the rat brain, in structures 
including the cerebral cortex, cerebellum, and brainstem   
with greater expression in the neuropil as compared to   
cell bodies [10]. PKGII expression has been also reported in 
thalamus, outer layers of cerebral cortex, septum, amygdala, 
and olfactory bulb [21, 53]. 
3. REGULATION OF cGMP SIGNALING 
3.1. Compartmentalization and Crosstalk: Two Important 
Concepts  
  A variety of extracellular cues are able to initiate com-
mon intracellular signaling cascades, such as the cGMP sig-
nal transduction pathway, to produce distinct biological ef-
fects. It is unclear how exactly different ligands are capable 
of producing distinct messages through intracellular signal-
ing cascades resulting in unique cellular responses despite 
acting through cGMP, which is their common second mes-
senger intermediate. The concept of “compartmentalization” 
of cyclic nucleotide signaling in time and space has been 
proposed to account for this discrepancy. 
  Through the use of fluorescence energy resonance trans-
fer (FRET) techniques in which specially engineered fluo-
rescent probes are used to detect cyclic nucleotide levels in 
cells, much information has been gained regarding the 
propagation of the cyclic nucleotide signal in time and space. 
For example, observations of cAMP signaling in live cells 
using FRET have demonstrated that the accumulation of   
this small second messenger occurs in local “cAMP pools” 
[54]. This observation has led to the idea of “compart- 
mentalization” or the presence of confined compartments/ 
microdomains of cAMP signaling resulting from physical 
barriers in the cell that restrict the diffusion of cAMP, form-
ing gradients [55]. Macromolecular complexes comprising 
this physical barrier are composed of the A-Kinase anchor-
ing proteins (AKAPs), which create a scaffold or platform 
for interactions between regulatory and effector proteins 
relevant to cAMP signaling also present in the complex [34]. 
  One of the target effectors of cGMP is PKG. PKG is ac-
tivated when two molecules of cGMP bind to the regulatory 
subunits of this protein, releasing the autoinhibitory domain 
of the regulatory subunit from the catalytic subunit. Acti-
vated PKG then can go on to phosphorylate any number of 
different downstream targets to result in distinct cellular re-
sponses. Interestingly, PKGs participate in the negative 
feedback of cGMP signaling by phosphorylating and activat-
ing PDEs, the enzymes that degrade cyclic nucleotides, to 
decrease the levels of cGMP [56]. By regulating the levels of 
cyclic nucleotides, PDEs are thought to play a critical regula-
tory role in fine-tuning the cGMP message in both time and 
space. As PDEs are expressed in specific subcellular loca-
tions, it has been proposed that PDEs are strategically placed 
in cells and act as “sinks” to increase the turnover of cyclic 
nucleotides and thereby dampen the cyclic nucleotide mes-
sage [54]. PDEs recruited to macromolecular complexes 
through their activation by PKG phosphorylation could po-
tentially decrease the amount of cGMP in a distinct subcellu-
lar microdomain. Pharmacological PDE inhibitors are hy-
pothesized to result in abnormal cyclic nucleotide signaling 
by disrupting local cyclic nucleotide pools so that they “spill 
over” from their confined compartments to inappropriately 
activate target effectors previously not accessible [55]. 
  The presence of cGMP pools located in specific cellular 
regions suggests that different biological effects could be 
produced through the action of different combinations of 
PKGs and PDEs present in macromolecular complexes at 
these specialized cyclic nucleotide microdomains [54]. 
While the details of “compartmentalization” of different 
cGMP messages need to be clarified, the concept provides an 
intriguing explanation to the question of how different ex-
tracellular cues working through the same intracellular mes-
senger can produce different biological outcomes. Therefore, 
it is likely that the cGMP message is subject to compartmen-
talization, with macromolecular complexes composed of 
AKAPs, PKG, and PDEs confining cGMP into specialized 
microdomains or localized pools of cGMP [55]. Further 
studies are needed to determine which AKAPs coordinate 
cGMP hydrolyzing PDEs and PKG to regulate the amount of 
cGMP.  
  The concept of “crosstalk” in intracellular signaling 
transduction cascades refers to the ability of components 
from one signaling pathway to interact with components of 
another signaling pathway. There is already ample evidence 
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with PDEs specifically hypothesized to act as points of inter-
section between these two pathways [57, 58]. Given the evi-
dence that PDEs are targeted to distinct subcellular locations 
where they potentially regulate the levels of cyclic nucleo-
tides by acting as “sinks” within “compartmentalized”   
anchored signaling complexes to define microdomains of 
cyclic nucleotides within cells, it is plausible that PDEs 
could also operate as points of crosstalk control in the cell 
between cAMP and cGMP signaling networks. Two dual 
substrate PDEs, namely PDE2 and PDE3, have emerged   
as likely candidates to coordinate the interaction between 
intracellular cyclic nucleotide signaling pathways [57]. 
3.2. Synthesis Regulation: NO/sGC/cGMP  
  Nitric oxide (NO) is a free radical and a small molecule 
gas that is capable of diffusing across membranes where it 
can act as a second messenger in signaling cascades. Specifi-
cally, NO acts as the intracellular ligand for the soluble 
guanylate cyclase (sGC or NO receptors), which are cGMP 
synthetic enzyme present in the cytosol. Upon binding of NO 
to sGC, cGMP is synthesized from GTP. Therefore, NO is 
an important regulator of cGMP levels because of its activat-
ing effects on sGC. In the nervous system, NO/cGMP signal-
ing mediates long-term potentiation (LTP) and NO was con-
sidered as a retrograde messenger [59]. Specifically, activa-
tion of NMDA (N-methyl-d-aspartate) receptors have been 
found to increase postsynaptic synthesis of NO by Ca
2+/ 
calmodulin dependent neuronal NOS (NO synthase, NOS-
1/nNOS). The diffusible NO can then activate sGC that re-
sult in the presynaptic production of cGMP and neurotrans-
mitter release. Soluble GCs occurs as two isoforms: NO-
GC1 and NO-GC2. Interestingly, it has been reported that 
both NO-GCs are required for LTP and that NMDA-induced 
NO increases cGMP only in the presence of NO-GC1, which 
have implied different synaptic localizations for NO-GC1 
and NO-GC2. This evidence indicates that the compartmental 
regulation of cGMP signaling is involved in synaptic plastic-
ity and that sGC may play an important role in the precise 
spatial control of cGMP synthesis.  
3.3. Degradation Regulation: PDE2, PDE3 and PDE5. 
  PDE2, 3 and 5 are relevant regulatory PDE’s because 
they may be activated or inhibited by cGMP and they effect 
changes in the levels of cGMP or cAMP. 
PDE2 
  The binding affinities of PDE2 for cAMP (Km=30 M) 
and cGMP (Km=10 M) reveal that PDE2 can bind both cy-
clic nucleotides equally and is capable of hydrolyzing both 
cAMP and cGMP [57]. However, PDE2 is referred to as the 
“cGMP-stimulated cAMP PDE” because cGMP binding to 
GAF (cGMP-biding PDE, Anabaena a denylyl cyclases,   
Eschericihia coli FhlAs) domains present in the N-terminal 
region allosterically stimulates the cAMP hydrolyzing activ-
ity of PDE2, resulting in decreased cAMP levels. Cyclic 
GMP binding to the GAF domain of PDE2 results in a con-
formational change to the catalytic domain of PDE2, chang-
ing the kinetics (decreasing Km and increasing Vmax values) 
of PDE2 towards the cAMP substrate, and increasing the 
hydrolyzing activity of PDE2 specifically towards the break-
down of cAMP into 5’AMP. Interestingly, PDE2A has three 
splice variants, among which, PDE2A3 is entirely membrane 
associated in the mouse brain. Moreover, in cultures of hip-
pocampal neurons, PDE2A co-localized with the synaptic 
marker synaptophysin, in a punctate pattern. Therefore, 
PDE2A represents a key point of compartmentalized cross-
talk between cAMP and cGMP signaling. 
PDE3 
  Cyclic AMP and cGMP act as mutually competitive sub-
strates for PDE3, and the binding affinities of PDE3 for 
cAMP (Km=0.08  M) and cGMP (Km=0.02  M) demon-
strate that PDE3 is indeed a dual substrate PDE capable of 
binding each cyclic nucleotide substrate with similar affinity 
[57]. However, as PDE3 demonstrates a higher rate of ca-
talysis for cAMP (10- fold higher Vmax) versus cGMP, it is 
referred to as “cAMP preferring.” PDE3 has also been called 
the “cGMP-inhibited cAMP PDE” because of in vitro ex-
perimental evidence that cGMP can inhibit the cAMP hydro-
lyzing activity of PDE3 to increase the levels of cAMP [60]. 
Evidence of a putative PKG phosphorylation site in the N-
terminal domain of PDE3 indicates that PDE3 activity can 
be indirectly influenced by cGMP via downstream kinase 
effects of PKG to phosphorylate PDE3 [57]. PDE3 therefore 
represents a point of crosstalk control, another example of a 
cAMP hydrolyzing PDE that might be a target of regulation 
by cGMP-mediated signaling.  
PDE5 
  PDE5 is referred to as the “cGMP-stimulated cGMP 
PDE,” as the N-terminal region of the PDE5 gene contains a 
GAF domain where cGMP can bind, as well as a site for 
phosphorylation by PKG. Cyclic GMP allosteric binding to 
the GAF domain of PDE5 stimulates the enzyme, decreasing 
the Km to increase the affinity of the binding site for cGMP 
as well increasing the catalytic activity of PDE5 to hydrolyse 
cGMP. By binding to the GAF domain of PDE5, cGMP is 
thought to increase the accessibility of the Ser102 residue of 
PDE5 to phosphorylation by PKG, thereby activating the 
enzyme. There is evidence that PKA might also phosphory-
late PDE5, an intriguing example of possible crosstalk   
regulation between cAMP and cGMP signaling pathways 
[61]. 
4. THE ROLE OF cGMP SIGNALING IN BRAIN 
PLASTICITY AND MDD 
4.1. The Neuroplasticity Hypothesis of MDD 
  Although the currently accepted mechanism of action of 
available antidepressants suggests the involvement of the 
monoamine system in MDD, increasing evidence has sup-
ported that neuroplasticity is disturbed in this disorder. Neu-
roplasticity includes functional synaptic plasticity (regulation 
of synaptic transmission) and structural plasticity (such as 
adult neurogenesis and permanent morphological changes of 
synaptic structure).  
  Functional synaptic plasticity is mediated by glutamate 
signaling. Glutamate binds to postsynaptic NMDA receptor, 
increasing synaptic calcium flux, which induces the activa-
tion of kinases that is critical for the early phase of LTP, 
such as calcium-calmodulin-dependent kinase II (CaMKII). 720    Current Neuropharmacology, 2011, Vol. 9, No. 4  Reierson et al. 
CaMKII can trigger insertion of new AMPA [2-amino-3-(5-
methyl-3-oxo-1,2-oxal-4-yl) propanoic acid] receptors in the 
postsynaptic membrane by phosphorylating the GluR1 (glu-
tamate receptor type 1) subunit of the AMPA receptor, 
which results in activation of “silent synapsis” and long-term 
potentiation (LTP) [62]. LTP strengthens synaptic transmis-
sion, representing occurrence of memory, while long-term 
depression (LTD) decreases synaptic function, representing 
weakening of memory. In experimental animals, severe 
stress can impair LTP and enhance LTD in the hippocampus 
[63-65]. Both electroconvulsive shock and chronic antide-
pressant treatments reverse impaired LTP in animal models 
of depression [66, 67]. 
  In the late phase of LTP, the accumulation of cAMP and 
calcium activate signal transduction cascades. PKA, MAPK 
and CaMKII translocate to the cell nucleus and phosphory-
late the transcription factor CREB  (cAMP response element-
binding), which in turn induces gene transcription and   
protein synthesis of brain derived neurotrophic factor (BDNF) 
and vascular endothelial growth factor (VEGF), leading to 
changes in the synaptic structure [24, 25, 33]. Adult neuro-
genesis occurs in the dentate gyrus region of the hippocam-
pus and it is supposedly regulated by LTP and activation of 
CREB. In animal models, chronic stress induces morphol-
ogic changes in the hippocampus and prefrontal cortex: the 
number of dendritic spines and synapses decrease, and neu-
rogenesis in the dentate gyrus is impaired [68, 69]. In clinical 
research, structural imaging also demonstrated hippocampal 
atrophy in MDD patients [70, 71]. Electroconvulsive shock 
and chronic antidepressant treatments can increase neuro-
genesis, improve the rate of proliferation and the survival of 
neurogenesis through the cAMP-CREB cascade [72-74]. 
4.2. cGMP and Functional Synaptic Plasticity 
  Evidence indicates that cGMP signaling plays a pivotal 
role in LTP. Inhibitors of PKG/sGC can block the induction 
of LTP. During tetanus induced LTP, PKG/sGC is activated 
leading to transient increases in cGMP levels and activation 
of PKG. Cyclic GMP signaling is transduced by down-
stream effectors such as CNG, PKGI/cGKI, PKGII/cGKII, 
and cGMP-activated phosphodiesterases, which underlie the 
crosstalk between cAMP and cGMP signaling. It has been 
reported that the presynaptic NO/cGMP signaling induced 
during LTP facilitates glutamate release via hyperpolariza-
tion of activated cyclic nucleotide-gated channels, which in 
turn enhances synaptic transmission [75]. The downstream 
events of cGMP/PGK signaling are under investigation, but 
increasing evidence has indicated their critical role in LTP. 
PKGI/cGKI is colocalized with synaptophysin and concen-
trated in a punctate pattern, which is activated and phos-
phorylates presynaptically and postsynaptically VASP 
(vasodilator-stimulated phosphoprotein) during potentiation, 
increasing aggregation of synaptic proteins [76]. PKGII/cGKII 
interact with GluR1 (Glutamate receptor1), a subunit of AMPA  
(2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) 
receptor, regulating AMPA receptor trafficking, which   
facilitate the insertion of AMPA receptor and activation of 
“silent synapses” [77, 78]. 
  During the late phase of LTP, cGMP/PKG signaling causes 
release of calcium from ryanodine-sensitive stores, which 
phosphorylate CREB in parallel to cAMP/PKA signaling 
induced CREB phosphorylation, and in turn induces synaptic 
protein synthesis and synaptic structural changing [79-81]. 
4.3. cGMP and Neurogenesis 
  It has been demonstrated in an animal model of stroke 
that treatment of stroke with NO donor or the PDE5 inhibitor 
sildenafil increases brain cGMP levels and induces prolifera-
tion of progenitor cells in the subventricular zone (SVZ) and 
dentate gyrus as well as the number of immature neurons 
[82, 83]. An in vitro study using neurospheres isolated from 
SVZ indicates that the cGMP-enhanced neurogenesis occurs 
through PI3-K/Akt/GSK-3 (phosphoinositide 3-kinase/protein 
kinase B (aka AKT)/glycogen synthase kinase 3) pathway. 
Sildenafil caused a 4- to 6-fold increase in PKGII gene   
expression in neurospheres, which has implied a putative 
role of PKGII in cGMP-induced neurogenesis. Interestingly, 
clinical trials with PDE5 inhibitors indicate that these drugs 
might also have mood-enhancing effects as well as memory 
enhancing effects; although further studies are needed to 
determine whether these effects are related to increased 
cGMP levels and neurogenesis [84]. 
  Cyclic GMP concentration relative to cAMP in neurons 
is involved in the modulation of dendritic and axonal guid-
ance [85-87]. In vitro studies support the concept that the 
ratio of cAMP to cGMP sets the polarity of nerve growth-
cone turning: high ratios favour attraction, whereas low ra-
tios favour repulsion [86]. There is a reciprocal regulation 
between cAMP and cGMP in cultured hippocampal neurons; 
small alterations in one cyclic mononucleotide are physio-
logically relevant and yield reciprocal alterations in the 
other. Localised cAMP and cGMP activities in undifferenti-
ated neurites promote and suppress axon formation, respec-
tively, and exert opposite effects on dendrite formation [88]. 
Therefore the intricate interaction between cAMP and cGMP 
might contribute to integrate the new neurons into existent 
neurocircuits. 
  In our lab, we have found that 8-week treatment with 
fluoxetine and amitriptyline increased hippocampal cGMP 
content, with decreased hippocampal gene expression of 
PDE3, PDE4, and PDE5 and unchanged cAMP levels. We 
also found decreased hippocampal cAMP signaling, with 
unchanged cGMP levels and increased PDE3, PDE4, and 
PDE5 gene expression following chronic imipramine treat-
ment. An understanding of the interconnectedness of cAMP 
and cGMP signaling pathways can be used to reconcile these 
seemingly divergent results. Our findings suggest that an 
increase of cGMP signaling pathway relative to cAMP sig-
naling pathway in the hippocampus could be relevant to an-
tidepressant action following chronic antidepressant admini-
stration. More research is needed to understand whether in-
creases in hippocampal cGMP induced by chronic antide-
pressant treatment enhances neurogenesis and whether the 
compartmentalized interplay of cGMP and cAMP facilitates 
the incorporation of new neurons into the circuit. 
4.4. NO and Serotonin Transporter (SERT) 
  NO has also been proposed to influence the activity of 
the serotonin reuptake transporter [89]. Selective serotonin 
reuptake inhibitor (SSRI) antidepressants are known to in-cGMP Signaling, Phosphodiesterases and Major Depression Disorder  Current Neuropharmacology, 2011, Vol. 9, No. 4    721 
crease the amount of serotonin at the synapse by inhibiting 
serotonin transporter (SERT); therefore, SERT has been hy-
pothesized as an important player in the pathophysiology of 
MDD. A recent proteomics based approach identified NOS1 
as one of the proteins that physically interacts with the PSD-
95/DISC large/ZO-1 (PDZ) domain of SERT [90]. HEK-293 
cells transfected with NOS1 and YFP (yellow fluorescent 
protein)-tagged SERT were used to demonstrate that a 
physical interaction between these two proteins can be   
recapitulated in an in vitro cell culture model. Further, the 
interaction of NOS1 with SERT was found to decrease 5-HT 
uptake, indicating that SERT activity was decreased upon 
physical interaction with NOS1. In light of these results, 
NOS1 has been hypothesized as a putative endogenous anti-
depressant by decreasing the activity of SERT to increase 
extracellular 5-HT [59].  
4.5. cGMP Signaling and MDD 
4.5.1. Genotyping SNPs in cGMP Signaling Components 
(NOS1 and PDEs) 
  Only one study has investigated the relationship between 
a specific NOS1 genetic variant (C2767) and MDD. The 
authors chose to study this genetic variant as a previous ge-
netic study had found an association of this single nucleotide 
polymorphism (SNP) and schizophrenia [91]. In this study of 
114 MDD patients treated with fluoxetine for 4 weeks, the 
NOS1 C2767 polymorphism was not significantly associated 
with susceptibility to MDD or to antidepressant treatment 
response when compared to 82 controls. However, the 
authors of that study have noted that 4 weeks fluoxetine 
treatment might not have been sufficiently long enough to 
achieve antidepressant treatment response and therefore they 
could not exclude the possibility that a longer duration of 
treatment could have yielded different results. Another ge-
netic association analysis performed in a sample of Japanese 
patients with MDD and bipolar disorder failed to detect an 
association of 8 weeks fluvoxamine treatment with the 
rs41279104 or ex1c SNP in the NOS1 gene in MDD pa-
tients. The researchers acknowledged that using linkage 
disequilibrium and a larger sample size could yield different 
results [92]. 
  Our lab has previously found that several SNPs in cGMP 
degrading PDE genes are related to the susceptibility to 
MDD and to antidepressant treatment response [93]. In that 
study, Mexican-American men and women MDD patients 
and controls were treated for 8 weeks with desipramine or 
fluoxetine and blood samples were taken for genotyping. 
Two SNPs in a cGMP specific PDE gene (rs729861 in 
PDE9A) and a dual substrate PDE gene (rs3770018 in 
PDE11A) were significantly associated with MDD at a Bon-
ferroni corrected significance level of <0.0006 comparing 
control and depressed groups. Within the depressed group, 
two SNPs in dual substrate PDE genes (rs1549870 in 
PDE1A and rs1880916 in PDE11A) were associated with 
attained remitter and non-remitter status, indicative of anti-
depressant treatment response. Remission is defined as 
HAM-D (Hamilton Depression Rating Scale) score of less 
than 8. Although our findings indicating associations of 
SNPs in PDE1A, PDE9A, and PDE11A with MDD and an-
tidepressant treatment response failed to reproduce in an 
independent sample of MDD patients versus controls (the 
sequenced treatment alternatives to relieve depression/ 
STAR*D sample) [94, 95]. Recent post-mortem data support 
the disruption of PDE signaling system in the cerebellum of 
subjects with MDD, specifically, PRKG1 (protein kinase, 
cGMP dependent regulatory type 1) was upregulated [96]. 
The concept that genetic variations in cGMP-related PDEs 
could be relevant to susceptibility to MDD and to anti- 
depressant treatment response provides a novel target for anti- 
depressant drug development in the cGMP signaling system.  
4.5.2. Behavioral Phenotype of cGMP Signaling Pathway 
knockout Mice 
NOS1-/-, GCs-/- 
  NOS1 knockout mice display aggressive and impulsive 
behaviors [97, 98]. Other roles for NOS1 in the behavioral 
sensitization to cocaine [99], the behavioral response to in-
flammatory pain [100], and the development of social mem-
ory [101] have been proposed from behavioral assessments 
of NOS1 knockout mice. Knocking out either of the two  
subunits of the GC enzyme, 1 or 2, in mice leads to ab-
sent LTP in the visual cortex, but the application of a cGMP 
analog combined with theta burst stimulation was capable 
restoring LTP [102]. 
PDE1B-/-, PDE10A-/-, PDE11A-/- 
  Mice deficient in the dual substrate PDE1B gene are re-
ported to display hyperactivity when compared to wild-type 
mice in baseline measures of locomotor activity, with exag-
gerated hyperactivity in response to amphetamine and meth-
amphetamine [103-105]. One study found additional defects 
in hippocampal spatial learning in PDE1B mutants, with an 
increase in path length to find a hidden platform in the Mor-
ris Water Maze [104]. Another study reported no significant 
differences in behavioral tests of anxiety-like behaviors   
(elevated plus maze), depressive-like behaviors (forced   
swim test), nociception (hot plate), or models of cognition 
(passive avoidance test and acquisition of conditioned   
avoidance response) in PDE1B knockout mice [103]. 
  Behavioral phenotype assessment for mice deficient in 
the dual substrate PDE10A gene reveal decreased baseline 
locomotor activity, with decreased locomotor response to 
PCP and MK-801 as well as defects in the acquisition of the 
conditioned avoidance response [106, 107]. No significant 
differences were reported in behavioral tests of anxiety, de-
pression, and nociception or in the passive avoidance and 
Morris Water Maze tasks of cognition [107]. 
  Deletion of PDE11A results in a series of phenotypes 
associated with dysfunction of ventral hippocampus. The 
PDE11A-/- mice exhibit hyperactive locomotor behavior and 
increased sensitivity to NMDA receptor inhibitor MK 801. 
However, they tested normal in hippocampus-associated 
memory and anxiety/ depressive related behavior evaluations. 
PKG/cGKII-/- 
  PKG/cGKII knockout animals showed enhanced anxiety-
like behavior in the light-dark box test and elevated O-maze 
test. They were hyposensitive to the hypnotic effects of   
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4.5.3. Behavioral Phenotypes with cGMP Signaling   
Pharmacotherapy 
NOS Inhibitor  
  Several studies have investigated the effects of NOS1 
inhibition on behavioral tests of anxiety and depression. In 
these studies, NOS1 inhibition is achieved either through 
pharmacological means, using NOS1 inhibitors or via silenc-
ing the NOS1 gene. Results from these studies have led to 
the hypothesis that NOS1 inhibition has an antidepressant 
effect. Intra-hippocampal administration of the NOS1 inhibi-
tor 7-nitroindazole decreases immobility time of rodents on 
the forced swim test [109]. Another NOS1 inhibitor, 1-(2-
trifluoromethylphenyl)-imidazole (TRIM) can augment the 
effects of imipramine, citalopram, fluoxetine, and tianeptine 
on the forced swim test [110]. 
  Male mice deficient in NOS1 were shown to display ag-
gressive and impulsive behavior, thought to be related to 
decreased 5-HT receptor function and reuptake transporter 
activity [98]. Although chronic, 28 day treatment with the 
SSRI fluoxetine could not mitigate the anxiogenic phenotype 
of NOS1 knockout mice, hippocampal NOS1 expression was 
decreased in wild-type mice following chronic treatment 
with fluoxetine [97]. The chronic mild stress model of de-
pression used in mice was shown to increase hippocampal 
NOS1 expression both acutely after 4 days and chronically 
after 21 or 56 days, with a coincident finding of decreased 
hippocampal neurogenesis in wild-type mice. In contrast 
NOS1 knockout mice were resistant to the effects of chronic 
mild stress on depressive-like behaviors and did not display 
decreased hippocampal neurogenesis [111]. In another study, 
chronic stress was once again shown to increase NOS1 and 
NOS2 expression in neocortex and hippocampus, with the 
administration of the non-specific NOS inhibitor N(omega)-
nitro-L-arginine methyl ester (L-NAME) (10 mg/kg) increas-
ing depressive-like behaviors [112]. 
PDE Inhibitors (PDEI) 
  Mice treated acutely with sildenafil displayed increased 
anxiety-like behaviors in the elevated plus-maze test, and 
this effect was reversed by pretreatment with the guanylyl 
cyclase (GC) inhibitor, methylene blue [92]. In contrast, an-
other study in mice found that sildenafil decreased anxiety-
like behaviors in the elevated plus-maze and open field tests 
of anxiety only when combined with high dose of L-arginine, 
and when sildenafil was given alone, it did not produce anxi-
ety-like behaviors [113]. Sildenafil given chronically for 
seven days to rats in combination with atropine, a muscarinic 
receptor blocker displayed an antidepressant-like effect in 
the FST and combination treatment was as effective as 
chronic fluoxetine on decreasing immobility in the FST [8]. 
One study has reported an increase in aggressive behavior in 
mice one week following discontinuation of a chronic silde-
nafil treatment regimen (4 weeks, 10mg/kg sildenafil) [114]. 
Pretreatment with acute sildenafil has effects on behavioral 
tests of depression, preventing the decrease in immobility 
that normally occurs with the administration of acute adeno-
sine [115], venlafaxine [11], and bupropion [116], but not of 
fluoxetine [117]. The results from studies on the effects of 
sildenafil in behavioral tests of depression and anxiety are 
complicated by differences in methodology including dosing 
regimens and behavioral tests. Different from the other 
cGMP signaling targeting drugs, the PDE2 inhibitors exhibit 
a univocal anxiolytic effect. It has been reported that PDE2 
inhibitor Bay 60-7550 and ND7001 can induce anxiolytic 
effect in both stress and non-stressed mice, which can be 
antagonized by GCs inhibitor ODQ [118]. The oxidative-
induced anxiety can also be reversed by Bay 60-7550 [119]. 
5. PHARMACOTHERAPY TARGETING cGMP   
SIGNALING (TABLE 1) 
5.1. NO Donors 
    Although inhaled NO gas is used clinically to relieve 
pulmonary hypertension, NO gas is unfortunately highly 
reactive and can quickly oxidize to nitrogen dioxide. NO 
donor drugs resolve this issue by acting as carriers for NO, 
providing stability until appropriate release of the NO mole-
cule is desired. There are three major classes of NO donor 
drugs: organic nitrates, diazeniumdiolates and S-nitrosothiols. 
The organic nitrates are the only NO donor drugs that are 
currently approved for clinical use and include the heart 
medications nitroglycerin and sodium nitroprusside (SN). 
Nitroglycerin, also known as glyceryl trinitrate (GTN), is 
used to acutely relieve angina pectoris (chest pain) and SN  
is used in the setting of a hypertensive crisis to quickly   
decrease blood pressure. The diazeniumdiolates, also known 
as NONOates, are composed of a diolate group bound via a 
nitrogen atom to a nucleophile adduct. The diazeniumdio-
lates are at present used experimentally in models of cardio-
vascular disease and include diethylamine NONOate (DEA/ 
NO), spermine NONOate (SPER/NO), PROLI/NO, V-
PYRRO/NO, and JS-K/NO. S-nitrothiols, also known as 
thionitrites, are composed of a thiol connected to a NO moi-
ety by a single chemical bond. The S-nitrothiols are also 
currently used experimentally in models of cardiovascular 
disease include S-nitroso-glutathione (GSNO), S-nitroso- 
N-acetylpenicillamine (SNAP) and S-nitroso-N-valeryl- 
penicillamine (SNVP) [120]. 
5.2. sGC/NO Receptor Agonists 
  Several stimulators or activators of the soluble GC en-
zyme (sGC), developed by Bayer Healthcare (Leverkusen, 
Germany), are currently being tested in experimental and 
clinical settings. The sGC stimulator drugs include BAY 41-
2272, BAY 41-8543 and BAY 63-2521 (riociguat). Rio-
ciguat is currently being tested in clinical trials for the treat-
ment of chronic thromboembolic pulmonary hypertension as 
well as in pulmonary arterial hypertension [121]. The sGC 
activator drug BAY 58-2667 (cinaciguat) is currently being 
tested in clinical trials for its use in the treatment of acute 
decompensated heart failure [122].   
5.3. PDE Inhibitors (PDEI) 
  There is growing interest in the clinical utility of PDE 
inhibitor (PDEI) drugs as these pharmacologic agents   
can increase levels of cyclic nucleotides to influence cell 
responses [123, 124]. Some PDEI drugs demonstrating   
selective inhibition of PDE3 or PDE5 enzymes are approved 
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acquired, most of these agents are still in development. 
PDE1Is include MMPX and vinpocetine. PDE2Is include 
BAY 60-7550 and EHNA. PDE3Is include amri-
none/inamrinone, anagrelide, cilostamide, cilostazol, enoxi-
mone, milrinone, siguazodan, and trequinsin. Anagrelide 
(Agrylin) and cilostazol (Pletal) are used clinically to 
treat thrombocytopenia and peripheral vascular disease, re-
spectively [125, 126]. Amrinone/inamrinone (Inocor) and 
milrinone (Primacor) are used to treat congestive heart 
failure [127]. Treatment with PDEIs is hypothesized to have 
a neuroprotective effect; in one in vitro study, 5-10 μM tre-
quinsin (PDE3I) and vinpocetine (PDE1I) was able to pre-
vent the neurotoxic effects of different models of cell injury 
following their application in rat cortical cell culture. It was  
hypothesized that the neuroprotective of these PDEIs   
could occur through the suppression of the cell cycle element 
cyclin D1 and the pro-apoptotic factor caspase 3 [128]. 
  PDE5Is include acetildenafil, avanafil, icariin, lodenafil, 
mirodenafil, MY-5445, sildenafil, T-0156, tadalafil, thiome-
thisosildenafil, udenafil, and vardenafil. Sildenafil (Via-
gra), tadalafil (Cialis) and vardenafil (Levitra) are used 
clinically to treat erectile dysfunction; sildenafil (Revatio) 
is also used to treat pulmonary hypertension [119]. PDE9Is 
include BAY 73-6691 and SCH-51866 [62]. PDE10Is in-
clude papaverine and PF-2545920. There are currently no 
inhibitors demonstrating selectivity for PDE6 or PDE11.  
  The PDE5 inhibitor sildenafil competitively inhibits the  
binding pocket of the catalytic domain of PDE5 so that   
cGMP is unable to bind and become hydrolyzed to 5’GMP;  
blockade of PDE5 by sildenafil therefore results in increased  
cGMP levels [124]. Sildenafil is administered orally in tablet  
formulations of the following doses: 25 mg, 50 mg or 100  
mg. The bioavailability of sildenafil following oral admini- 
stration is 41% with metabolism or elimination primarily by  
the hepatic enzymes, CYP3A4 and CYP2C9 [129]. The   
absorption of sildenafil reveals that peak plasma concentra- 
tion is reached within 60 minutes after administration, with  
therapeutic drug levels from 200ng/mL to 440 ng/mL,   
corresponding to 0.4 M and 1 M, respectively. In the steady  
state, sildenafil displays a mean volume of distribution of   
105 L, indicative of distribution into tissues.  
6. CONCLUDING REMARKS 
  The search for mechanisms of antidepressant action has 
led to the investigation of changes in neuroplasticity follow-
ing antidepressant treatment. While the cAMP signaling cas-
cade in the cortex and hippocampus has received the most 
attention todate, accumulating evidence in rodents and hu-
mans suggests a role for cGMP signaling in stress induced 
disturbance of neuroplasticity and antidepressant action as 
well. In this review we have summarized the biology of 
cGMP signaling cascade in the brain and emergent data sup-
porting the role of NO/cGMP signaling in neuroplasticity 
and MDD. We suggest that functional synaptic plasticity 
starts with activation of glutamate system in the CNS; fur-
thermore, a growing body of evidence implicates a role of 
Table 1.  Pharmacological Therapy Targeting the cGMP System 
Type   Drugs    Effects 
Organic nitrate  Nitroglycerin (GTN) 
Sodium nitroprusside(SN) 
Cardiovascular disease 
diazeniumdiolate  Diethylamine NONOate (DEA/NO) 
Spermine NONOate (SPER/NO) 
PROLI/NO, VPYRRO/NO, JS-K/NO 
Cardiovascular disease 
NO donors 
S-nitrosthiols S-nitrosoglutathione(GSNO) 
S-nitroso-N-acetylpenicillamine(SNAP) 
S-nitroso-N-valerylpenicillamine(SNVP) 
Cardiovascular disease 
sGC/NO  
receptor agonist 
  BAY 41-2272, BAY 41-8543, 
BAY 63-2521, BAY 2667 
Cardiovascular disease 
PDE1I  MMPX, vinpocetine   Prevent neurotoxic effects 
PDE2I  BAY 60-7550, EHNA  Anxiolytic effect 
Amrinone, milrinone   Congestive heart failure 
anagrelide, cilostamide, cilostazol, enoximonesiguazodan,  Thrombocytopenia and peripheral vascular disease 
PDE3I 
trequinsin Prevent  neurotoxic  effects 
PDE5I  Sildenafil, tadalafil, vardenafil  Erectile dysfunction and pulmonary hypertension 
PDE9I  BAY 73-6691, SCH-51866, PF-4181366  Improve learning and memory 
PDE inhibitors 
PDE10I Papaverine,  PF-2545920   724    Current Neuropharmacology, 2011, Vol. 9, No. 4  Reierson et al. 
the glutamatergic system in the pathophysiology and treat-
ment of MDD [130]. Activation of glutamate receptors in-
creases in Ca
2+ levels at the postsynaptic neuron and stimu-
lates NO synthesis, which stimulates the NO/cGMP path-
way. NO can also act transynaptically at the presynaptic neu-
ron or surrounding cells. The presynaptic and postsynaptic 
cGMP signaling enhances synaptic transmission (Fig. 1), 
induces synaptic protein synthesis during the late phase of 
LTP and might facilitate neurogenesis through activation of 
several downstream substrates. It is beyond the scope of this 
review to discuss the immune/inflammatory aspects of NO 
and cGMP signaling pathway through the role of inducible 
nitric oxide synthase (NOS2). 
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